Treatment of Childhood Acute Myeloid Leukemia in Bulgaria

Autor: Milena Belcheva, Liliya R. Ivanova, Angelina A. Stoyanova, Valeriya Kaleva, Hristina Hristozova, Elina Peteva, Albena B. Muchinova, Hasan Burnusuzov, Ivan N. Mumdzhiev, Irena Vlahova, Dragan G. Bobev, Dobrin Konstantinov, Neofit Spasov, Konstantin N. Bachvarov, Mariya I. Spasova, Nadezhda N. Yurukova, Boryana E. Avramova, Maya N. Yordanova
Rok vydání: 2017
Předmět:
Male
Pediatrics
medicine.medical_specialty
Treatment protocol
Adolescent
lcsh:Medicine
Age at diagnosis
Newly diagnosed
Kaplan-Meier Estimate
acute myeloid leukemia
Treatment results
03 medical and health sciences
Young Adult
0302 clinical medicine
children
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Overall survival
Retrospective analysis
Medicine
Asparaginase
Humans
Bulgaria
Child
neoplasms
Retrospective Studies
relapse
business.industry
lcsh:R
Childhood Acute Myeloid Leukemia
Daunorubicin
Remission Induction
Complete remission
Hematopoietic Stem Cell Transplantation
Infant
Newborn

Infant
General Medicine
Survival Rate
Leukemia
Myeloid
Acute

Vincristine
030220 oncology & carcinogenesis
Child
Preschool

Prednisone
Female
Neoplasm Recurrence
Local

business
030215 immunology
Zdroj: Folia Medica, Vol 60, Iss 2, Pp 234-240 (2018)
ISSN: 0204-8043
Popis: Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge. Aim: To report the AML treatment results of the Bulgarian pediatric oncohematological centers. Materials and methods: Retrospective analysis of the treatment results of children and adolescents (age from 0 to 20 years) with primary AML. Unified AML BFM- backbone type treatment protocol is used. Results: This study included 97 newly diagnosed patients (44 girls and 53 boys) with AML in Bulgaria between 2003 and 2016. The median age at diagnosis was 10.2 years. The most frequent FAB-morphologic subtype was M2 followed by M4. First complete remission (CR1) was achieved in 83 patients (85.6%). The 13-year EFS was 49%, while the overall survival (OS) was 54.6%. Twenty seven (27.8%) patients relapsed, with only 5 of them being still alive towards the end of the study period. Conclusion: The EFS and OS for the children with AML in Bulgaria are comparable with those reported by other European groups. The prognosis of relapsed AML remains still unfavorable for the past 13 years.
Databáze: OpenAIRE